Teva has long-term plans for the Russian market

| By | TEVA

In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries.

In this regard, Teva Russia made an official comment to clarify the following: the countries scheduled for business closure are mostly located in Africa and the Middle East, where the company’s presence is small.

The Russian office continues to operate as usual, without any changes in its operating activities. The company is successfully developing the local manufacturing at its plant in Yaroslavl and has long-term plans for the Russian market, which remains a strategic one for Teva.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.